Infectious disease diagnostics and laboratory company CirrusDx, Inc. announced its acquisition of Dascena Inc.'s Houston-based laboratory business, Dascena Labs, LLC., according to a press release.
Through the acquisition, Cirrus Dx, Inc., also known as CirrusDx, hopes to bolster its current line of services, expanding its impact as a national laboratory while also strengthening its sequencing abilities. Dascena Labs is widely recognized as a renowned CLIA (Clinical Laboratory Improvement Amendments of 1988) laboratory capable of high-volume specialized testing. Its work has been featured in over 45 peer-reviewed journals, such as Applied Sciences and the American Journal of the Medical Sciences, according to its website. It has also received support from federal agencies such as the National Institutes of Health and the National Science Foundation.
"We are pleased to continue to drive growth," CirrusDx Managing Partner Kyle Armantrout said. "Acquiring the expertise and technology of Dascena Labs aligns with our services, allowing us to build on our current offerings and our mission to support long-term care centers, regional hospitals and health care providers."
CirrusDx is a vertically-integrated diagnostic company in possession of a CLIA High Complexity laboratory which offers advanced diagnostic assays and instrumentation. The company serves as a companion to biotechnology company Tetracore, which specializes in the development and manufacturing of infectious disease diagnostic assays.